Brief: Alphamab Oncology Says On Dec 17, NMPA Accepted Biologic License Application For KN035
21/12/2020 13:16
Dec 21 (Reuters) - Alphamab Oncology 9966.HK :
* ON DEC 17, NMPA ACCEPTED BIOLOGIC LICENSE APPLICATION FOR
KN035
Source text https://www1.hkexnews.hk/listedco/listconews/sehk/2020/1221/2020122100902.pdf
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)